Related Experiment Video
Updated: Oct 18, 2025

08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.1K
An Innovative Non-Pharmacologic Treatment for Delusional Misidentification in Persons with Major Neurocognitive
Anne E Adams1, Jennifer Rittereiser2, Alisha Garcia1,2,3,4,5
1Managing Director, Applied Research, SimpleC LLC.
Delaware Journal of Public Health
|October 4, 2021
Summary
A novel digital intervention effectively reduced misidentification delusions in individuals with Major Neurocognitive Disorder. This non-pharmacologic approach also improved patient behavior and lessened caregiver burden.
Area of Science:
- Neuroscience
- Psychiatry
- Gerontology
Background:
- Misidentification delusions involve false beliefs about identity, common in neuropsychiatric disorders.
- These delusions significantly burden individuals with Major Neurocognitive Disorder and their caregivers.
- Current treatments for misidentification delusions lack consistent efficacy.
Purpose of the Study:
- To evaluate an innovative non-pharmacologic, digital intervention for misidentification delusions.
- To assess the intervention's impact on care recipient behavior and caregiver burden.
Main Methods:
- Case study design describing two caregiver-care recipient dyads.
- Implementation of a novel non-pharmacologic, digital intervention.
- Assessment of changes in delusional misidentification, behavior, and caregiver burden.
Main Results:
- The digital intervention successfully reduced delusional misidentification in both dyads.
- Observed improvements in care recipient behavior were noted.
- Caregiver burden was significantly decreased following the intervention.
Conclusions:
- A non-pharmacologic, digital intervention shows promise for managing misidentification delusions.
- This approach offers a potential new strategy for improving quality of life for individuals with neurocognitive disorders and their caregivers.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
294
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
294
False Memories
180
False memories represent a cognitive distortion in which individuals recall events that did not happen, or remember them in an altered form. This phenomenon highlights the brain's constructive nature in processing and recalling memories, emphasizing that memory is not a perfect representation of past events but rather a dynamic reconstruction influenced by various factors.
One primary source of false memories is misattribution, where individuals incorrectly associate external information...
One primary source of false memories is misattribution, where individuals incorrectly associate external information...
180

